TOPRAZOLE 40/MG EC TAB 30/TAB

Indications

Approved Uses

Erosive esophagitis associated with GERD (healing) and maintenance of healing; pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Dosage & Administration

Dosing by Condition

Erosive esophagitis (healing): 40 mg PO once daily for up to 8 weeks (may consider an additional 8 weeks if not healed). Maintenance of healing: 40 mg PO once daily. Pathological hypersecretory conditions (e.g., Zollinger-Ellison): start 40 mg PO twice daily and titrate to acid control (some patients require higher doses).

Initial Dose

40mg once daily for erosive esophagitis.

Maintenance Dose

20-40 mg once daily

Maximum Dose

240mg per day has been administered for pathological hypersecretory conditions.

Children's Dosage

For erosive esophagitis (5 years and older): 20mg once daily for children weighing 15kg to <40kg; 40mg once daily for children weighing ≥40kg, for up to 8 weeks.

Dose Adjustment Notes

Renal impairment: no dose adjustment. Hepatic impairment: use caution in severe hepatic impairment; routine dose reduction is not generally required for the 40 mg tablet, but consider clinical monitoring and using the lowest effective dose.

How to Take

Swallow the enteric‑coated tablet whole with water; do not crush, chew, or split. Take once daily preferably 30-60 minutes before a meal (commonly before breakfast).

Side Effects

Common Side Effects

Headache, diarrhea, nausea, abdominal pain, flatulence (gas), vomiting, dizziness.

Safety & Warnings

Contraindications

Contraindicated in: (1) hypersensitivity to pantoprazole/other substituted benzimidazoles or excipients; (2) concomitant use with rilpivirine-containing products.

Warnings & Precautions

Warnings/precautions: symptomatic response does not exclude gastric malignancy; risk of C. difficile-associated diarrhea; long-term/high-dose use may increase fracture risk; hypomagnesemia with prolonged use (consider monitoring if long-term or with digoxin/diuretics); acute interstitial nephritis; cutaneous/systemic lupus erythematosus; consider B12 deficiency risk with long-term therapy; false-positive urine THC screens have been reported with some PPIs (class effect-use confirmatory testing if needed).

Age Restriction

Approved for children ≥5 years for healing of erosive esophagitis (EE); safety/efficacy not established in children <5 years.

Drug Interactions

Interaction Severity

MAJOR/CONTRAINDICATED: rilpivirine; avoid with atazanavir or nelfinavir (reduced absorption/virologic failure risk). MODERATE: high‑dose methotrexate (consider temporary PPI hold), warfarin (monitor INR), drugs with pH‑dependent absorption such as ketoconazole/itraconazole and iron salts (reduced absorption).

Food Interaction

Preferably take 30-60 minutes before a meal; it can be taken without food, but pre‑meal timing generally provides better acid control.

Special Populations

Pregnancy

Consult Doctor

Children

For erosive esophagitis (5 years and older): 20mg once daily for children weighing 15kg to <40kg; 40mg once daily for children weighing ≥40kg, for up to 8 weeks.

Kidney Impairment

No renal dose adjustment needed (including severe renal impairment).

Storage & Patient Advice

Stopping the Medicine

Short courses can be stopped when no longer needed; after prolonged/long-term use, consider tapering or step-down to reduce rebound acid hypersecretion and symptom recurrence.

Patient Counseling

Take exactly as prescribed. Swallow the enteric‑coated tablet whole with water; do not crush, chew, or split. Take preferably 30-60 minutes before a meal (often before breakfast) for best acid suppression. If you miss a dose, take it when remembered unless it is close to the next dose-do not double. Seek medical advice for severe/persistent diarrhea (possible C. difficile), new rash or joint pain (possible cutaneous lupus), or symptoms of low magnesium (muscle cramps, palpitations, seizures), especially with prolonged use. Long‑term therapy may be associated with low magnesium, vitamin B12 deficiency, and increased fracture risk-use the lowest effective dose and follow up if used long term. Prescription-only; do not share.

Monitoring Requirements

With long‑term therapy: consider magnesium monitoring (especially with diuretics/digoxin), assess for vitamin B12 deficiency if prolonged use, monitor for C. difficile-associated diarrhea, and consider bone fracture risk in high‑risk patients; if on warfarin, monitor INR when starting/stopping.

Pharmacology

Mechanism of Action

Irreversibly inhibits the gastric parietal cell H+/K+‑ATPase (proton pump), blocking the final step of acid secretion and reducing basal and stimulated gastric acid output.

Onset of Action

Initial acid suppression begins within ~2-3 hours after a dose; maximal effect typically requires 2-4 days of daily dosing.

Duration of Effect

Approximately 24 hours per dose (acid suppression persists about a day, though the pharmacodynamic effect can extend beyond plasma half‑life).

Bioavailability

Approximately 77%.

Excretion

Approximately 71% excreted in urine (mainly as metabolites) and about 18% in feces (biliary).

Protein Binding

Approximately 98%, primarily to albumin.

Product Information

Available Dosage Forms

For this PRODUCT: enteric‑coated (delayed‑release) oral tablet 40 mg (blister pack of 30).

Composition per Dose

Each enteric-coated tablet: Pantoprazole 40 mg (as pantoprazole sodium sesquihydrate)

OTC Alternatives

OTC options for mild/frequent heartburn include H2 blockers (e.g., famotidine) and antacids (aluminum/magnesium hydroxide, calcium carbonate); in some markets, low‑dose PPIs such as omeprazole 20 mg or esomeprazole 20 mg are OTC.

Gi Condition

Acid Reflux/GERD, Ulcer

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.